CA2286052A1 - Nouveau systeme bioadhesif d'administration de medicaments base sur des cristaux liquides - Google Patents

Nouveau systeme bioadhesif d'administration de medicaments base sur des cristaux liquides Download PDF

Info

Publication number
CA2286052A1
CA2286052A1 CA002286052A CA2286052A CA2286052A1 CA 2286052 A1 CA2286052 A1 CA 2286052A1 CA 002286052 A CA002286052 A CA 002286052A CA 2286052 A CA2286052 A CA 2286052A CA 2286052 A1 CA2286052 A1 CA 2286052A1
Authority
CA
Canada
Prior art keywords
composition
composition according
cubic
substance
crystalline phase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002286052A
Other languages
English (en)
Inventor
Lise Sylvest Nielsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sandberg Development AB
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2286052A1 publication Critical patent/CA2286052A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases, cochleates; Sponge phases

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Système d'administration de médicaments contenant une phase cristalline liquide, telle qu'une phase cristalline liquide cubique, hexagonale, hexagonale inversée, lamellaire, micellaire ou micellaire inversée. Ces compositions présentent un caractère unique, étant donné qu'elles contiennent, en tant que système d'administration: (A) une substance capable de générer une phase cristalline liquide et produisant des effets biopharmaceutiques appropriés, tels que, par exemple, une libération adéquate de la substance active, tout en possédant des propriétés bioadhésives, et (B) au moins une autre substance qui, sans exercer d'effet sensiblement négatif sur les propriétés biopharmaceutiques que possède la substance (A), soit participe à la constitution d'une phase cristalline liquide, soit dilue la proportion de phase cristalline liquide dans la composition, tout en conservant encore des propriétés biopharmaceutiques et une stabilité de conservation appréciables. Des exemples de substances (A) sont représentés par des esters d'acides gras, tels que, par exemple, glycérylmonooléate et glycérylmonolinoléate et des exemples de substances (B) sont représentés, par exemple, par des agents structurants, tels que des phospholipides et des tocophérols ou par des excipients acceptables sur le plan pharmaceutique.
CA002286052A 1997-04-17 1998-04-17 Nouveau systeme bioadhesif d'administration de medicaments base sur des cristaux liquides Abandoned CA2286052A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK0435/97 1997-04-17
DK43597 1997-04-17
PCT/DK1998/000159 WO1998047487A1 (fr) 1997-04-17 1998-04-17 Nouveau systeme bioadhesif d'administration de medicaments base sur des cristaux liquides

Publications (1)

Publication Number Publication Date
CA2286052A1 true CA2286052A1 (fr) 1998-10-29

Family

ID=8093507

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002286052A Abandoned CA2286052A1 (fr) 1997-04-17 1998-04-17 Nouveau systeme bioadhesif d'administration de medicaments base sur des cristaux liquides

Country Status (5)

Country Link
EP (1) EP0975331A1 (fr)
JP (1) JP2001524958A (fr)
AU (1) AU6919598A (fr)
CA (1) CA2286052A1 (fr)
WO (1) WO1998047487A1 (fr)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010003580A1 (en) * 1998-01-14 2001-06-14 Poh K. Hui Preparation of a lipid blend and a phospholipid suspension containing the lipid blend
WO2001010411A2 (fr) * 1999-08-06 2001-02-15 Max-Delbrück-Centrum für Molekulare Medizin Depot de principe actif implantable
US6465002B1 (en) 2000-03-13 2002-10-15 Brown University Research Foundation Liquid crystalline polymers
US20020153508A1 (en) 2000-06-29 2002-10-24 Lynch Matthew Lawrence Cubic liquid crystalline compositions and methods for their preparation
DE10057767A1 (de) * 2000-11-22 2002-05-23 Beiersdorf Ag Deodorant- und Antitranspirantprodukte mit einem Gehalt an dispersen Flüssigkristallen, welche kubische Phasen darstellen
DE10057770A1 (de) * 2000-11-22 2002-05-23 Beiersdorf Ag Hautpflegeprodukte mit einem Gehalt an dispersen Flüssigkristallen, welche kubische Phasen darstellen ,
US6656385B2 (en) 2001-02-21 2003-12-02 The Procter & Gamble Company Functionalized cubic liquid crystalline phase materials and methods for their preparation and use
US6936187B2 (en) 2001-02-21 2005-08-30 Matthew Lawrence Lynch Functionalized cubic liquid crystalline phase materials and methods for their preparation and use
EP1539099A4 (fr) * 2002-06-13 2009-03-18 Lyotropic Therapeutics Llc Phases cristallines liquides inversees comprenant des agents hydrophobes paraffiniques
KR100533460B1 (ko) * 2002-07-20 2005-12-08 대화제약 주식회사 난용성 약물의 가용화용 점막흡착성 조성물, 이를 이용한난용성 약물의 가용화용 제형 및 이들의 제조 방법
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
JP2007504256A (ja) * 2003-09-01 2007-03-01 メイン・ファ−マ・インタ−ナショナル・プロプライエタリ−・リミテッド 生物活性剤の送達のための組成物及び方法
SI1845942T1 (sl) 2005-01-14 2014-06-30 Camurus Ab Gnrh analogne formulacije
PL1848403T3 (pl) * 2005-01-14 2010-09-30 Camurus Ab Preparaty bioadhezyjne o działaniu miejscowym
US9649382B2 (en) 2005-01-14 2017-05-16 Camurus Ab Topical bioadhesive formulations
PL1843746T3 (pl) * 2005-01-14 2011-09-30 Camurus Ab Formulacje analogów somatostatyny
US8871712B2 (en) 2005-01-14 2014-10-28 Camurus Ab Somatostatin analogue formulations
GB0501364D0 (en) * 2005-01-21 2005-03-02 Camurus Ab Compositions
EP1843751B1 (fr) * 2005-01-21 2020-09-30 Camurus Ab Compositions lipidiques pharmaceutiques
WO2006083761A2 (fr) 2005-02-03 2006-08-10 Alza Corporation Solutions de solvant/polymere utilisees comme vehicules de suspension
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
US20090075860A1 (en) * 2005-04-28 2009-03-19 Japan Science And Technology Agency Transdermal absorption enhancer
JP5198261B2 (ja) 2005-06-06 2013-05-15 カムルス エービー Ｇｌｐ−１類似体製剤
US20080219935A1 (en) * 2005-07-08 2008-09-11 Sang-Hoon Kwak Phase Transitive Breath Care Products
EP2020990B1 (fr) 2006-05-30 2010-09-22 Intarcia Therapeutics, Inc Modulateur de flux en deux pieces avec conduit interne pour un assemblage d'administration osmotique.
AU2007284759B2 (en) 2006-08-09 2010-10-28 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
AU2008244523B2 (en) 2007-04-23 2012-02-16 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
GB0711656D0 (en) 2007-06-15 2007-07-25 Camurus Ab Formulations
GB0716385D0 (en) 2007-08-22 2007-10-03 Camurus Ab Formulations
EP2240155B1 (fr) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Dispositifs, formulations et méthodes d administration de plusieurs agents bénéfiques
GB0815435D0 (en) 2008-08-22 2008-10-01 Camurus Ab Formulations
EP2498754B1 (fr) * 2009-06-25 2018-06-06 Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. Mésophases hexagonales inverses (h ii) et leurs utilisations
RU2547990C2 (ru) 2009-09-28 2015-04-10 Интарсия Терапьютикс, Инк. Быстрое достижение и/или прекращение существенной стабильной доставки лекарственного средства
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
KR101494594B1 (ko) 2011-08-30 2015-02-23 주식회사 종근당 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
SG11201404230QA (en) * 2012-01-31 2014-10-30 Santen Pharmaceutical Co Ltd Non-aqueous liquid composition
SG11201407678YA (en) 2012-05-25 2014-12-30 Camurus Ab Somatostatin receptor agonist formulations
KR101586791B1 (ko) * 2012-12-28 2016-01-19 주식회사 종근당 ＧｎＲＨ 유도체의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
JP6289075B2 (ja) * 2013-01-25 2018-03-07 ロート製薬株式会社 外用組成物
KR101601035B1 (ko) 2013-02-28 2016-03-08 주식회사 종근당 키토산 및 액상결정 형성 물질을 포함하는 유전자 전달용 조성물
EP3016655A4 (fr) 2013-05-09 2017-04-12 Zeenar Enterprises Pty Ltd Formulation de niacine
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
WO2016195338A2 (fr) * 2015-05-29 2016-12-08 서울대학교산학협력단 Nanoparticules de cristaux liquides, procédé de préparation de celles-ci, système d'administration de médicament contenant des nanoparticules de cristaux liquides incorporées à un médicament lipophile
EP3302354B1 (fr) 2015-06-03 2023-10-04 i2o Therapeutics, Inc. Systèmes de mise en place d'implant
RU2760007C2 (ru) 2016-05-16 2021-11-22 Интарсия Терапьютикс, Инк. Полипептиды, селективные к рецепторам глюкагона, и способы их применения
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
WO2018129058A1 (fr) 2017-01-03 2018-07-12 Intarcia Therapeutics, Inc. Méthodes comprenant l'administration continue d'un agoniste du récepteur glp-1 et la co-adminstration d'un médicament
JP2022536234A (ja) * 2019-10-31 2022-08-15 ケミストリーアールエックス． ピリミジン誘導体含有組成物
CN114632059A (zh) * 2020-12-15 2022-06-17 南京海辰药业股份有限公司 一种包含瑞德西韦的静脉输注液体制剂及制备方法
CN112791047A (zh) * 2021-01-15 2021-05-14 中国人民解放军总医院第三医学中心 一种白藜芦醇层状液晶及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5262164A (en) * 1989-11-17 1993-11-16 The Procter & Gamble Company Sustained release compositions for treating periodontal disease
SE9200952D0 (sv) * 1992-03-27 1992-03-27 Kabi Pharmacia Ab Pharmaceutical carrier system containing defined lipids
GB9409778D0 (en) * 1994-05-16 1994-07-06 Dumex Ltd As Compositions
SE518578C2 (sv) * 1994-06-15 2002-10-29 Gs Dev Ab Lipidbaserad komposition
CA2231273A1 (fr) * 1995-10-12 1997-04-17 Lise Sylvest Nielsen Composition pharmaceutique pour l'administration d'un principe actif sur ou au travers d'une surface cutanee ou muqueuse

Also Published As

Publication number Publication date
JP2001524958A (ja) 2001-12-04
WO1998047487A1 (fr) 1998-10-29
EP0975331A1 (fr) 2000-02-02
AU6919598A (en) 1998-11-13

Similar Documents

Publication Publication Date Title
AU702030B2 (en) A pharmaceutical composition for administration of an active substance to or through a skin or mucosal surface
CA2286052A1 (fr) Nouveau systeme bioadhesif d'administration de medicaments base sur des cristaux liquides
US6228383B1 (en) Use of fatty acid esters as bioadhesive substances
EP0752855B1 (fr) Utilisation d'esters d'acides gras comme substances bioadherentes
EP2301525B1 (fr) Préparation topique d'ibuprofène
AU2004291162B2 (en) Composition and dosage form comprising an amphiphilic molecule as a suspension vehicle
US8920782B2 (en) Topical bioadhesive formulations
JPH08505850A (ja) 抗ウイルス局所用医薬組成物
RU2560677C2 (ru) Кожная композиция, включающая аналог витамина d и смесь растворителя и поверхностно-активных веществ
EP0662819B1 (fr) Emulsion pharmaceutique d'huile dans l'eau a action antivirale contenant de la 9-[(2-hydroxyethoxy)methyl]guanine (acyclovir) ou un sel ou ester de ladite substance
US9649382B2 (en) Topical bioadhesive formulations
ZA200604967B (en) Composition and dosage form comprising an amphiphilic molecule as a suspension vehicle
CZ2004778A3 (cs) Farmaceutická formule zahrnující cyklosporin a její použití
Kaur et al. A Review on study of buccal patches: current status of formulation and evaluation methods
JPH11509515A (ja) 新規な医薬処方
EP1043979B1 (fr) Compositions destinees a l'administration transcutanee et cutanee d'agents biologiquement actifs
CN114302707A (zh) 局部阿昔洛韦制剂及其用途

Legal Events

Date Code Title Description
FZDE Discontinued